Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q3 FY2015 Earnings Presentation
27 slides from Alembic Pharmaceuticals's earnings presentation, February 2015
Slide 1: Investor Presentation
Alembic Pharmaceuticals Limited Investor Presentation February 2015 BSE Code: 533573 NSE Code: APLLTD Bloomberg Code: ALPM:IN Reuters Code: ALEM.NS www.alembic-india.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 3: The Journey so far
The Journey so far 1971 1940 1907 Becomes 1st Indian company to Starts manufacturing cough syrup, Alembic Ltd. starts manufacturing manufacture Erythromycin vitamins, tonics and sculpture drugs tinctures and alcohol at Vadodara 1972 1961 Launched it under brand Penicillin plant inaugurated ‘ALTHROCI
Slide 4: Revenue Overview Q3FY15
Revenue Overview Q3FY15 % of the total sales 3 2 6 India Branded Formulations International Generics 14 49 API Export India Generics International Branded Formulations 26 API Domestic
Slide 5: R&D Infrastructure
R&D Infrastructure State-of-the-art Analytical & IPR infrastructure R&D facility F&D Capabilities Bio Equivalence Centre R&D centre has been Expertise in Drug State-of-the art 90- recognized by DSIR, Deliveries and Niche bedded Bio Centre Govt. of India formulations 100 Pilot studies High-end R&D We
Slide 6: R&D spends to continue rising
R&D spends to continue rising R&D spend as a % to sales 7.00 7 6 6.00 4.78 5.06 5 4.06 % of sales 4 3 2 1 0 FY11 FY12 FY13 FY14 YTD DEC FY15 • Highly talented pool of 350 research scientists working to address complex genericisation opportunities, novel drug delivery systems and new technology platf
Slide 7: State of the Art Manufacturing Facilities
State of the Art Manufacturing Facilities Formulations Located at Panelav, Gujarat USFDA, MCC, MHRA, ANVISA & TPD approved – for Generic exports Capacity - 5 bn tablets / capsules p.a. being expanded to 7 bn p.a. Located at Baddi, Himachal Pradesh WHO GMP approved Manufactures branded formulations a
Slide 8: Formulations business accounts for ~80% of revenues
Formulations business accounts for ~80% of revenues
Slide 9: Branded business continues to grow
Branded business continues to grow
Slide 10: Strong domestic market presence
Strong domestic market presence 1.74% market share (Ranked 20th) in Indian formulations market as per IMS MAT data 2 brands featured among Sustained dominance in top 100 and 5 among top anti-infective, analgesics, 300 brands in India as cough and cold segments per IMS MAT data Key Highlights Robust
Slide 11: Continued shift towards Specialty therapies
Continued shift towards Specialty therapies Therapy Dominance 100 90 % of Domestic Formulations 80 44 51 46 70 58 54 60 50 40 30 56 49 54 20 42 46 10 0 FY11 FY12 FY13 FY14 YTD Dec FY15 Specialty Acute
Slide 12: Therapy-wise Performance
Therapy-wise Performance DEC QTR 2014 DEC QTR 2013 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 11 1.83 32 31 12 1.54 24 37 Anti Diabetic 15 1.52 28 24 25 1.37
Slide 13: Marketing Divisions
Marketing Divisions Corazon Cardio-Diabetes Summit Megacare Specia Anti-infective Alcare Acute and Cold & Pharma Cough Gynecology Zenovi Maxis Enteron Specialty Gastroenterology Gastron Veterinary Dermatology Corium Animal Healthcare Orthopedics Osteofit Ophthalmology Eyecare Poultry High end Respir
Slide 14: Key Therapies & Brands
Key Therapies & Brands Therapeutic Segment-wise Break-up (Q3FY15) • Launched 6 product SKUs in the domestic market in Q3FY15, 28 product SKUs YTD DEC 14. % of total domestic formulation revenue Brand Name Therapeutic Area Ranking Azithral Anti-infective 35 Althrocin Anti-infective 65 Wikoryl Respira
Slide 15: Branded Export business in investment phase
Branded Export business in investment phase Products filed in key markets (South East Asia, CIS and East Africa) Focus on Rest of the Expected to be of critical World markets mass in 3 years Key Highlights
Slide 16: International Generics will be the growth driver
International Generics will be the growth driver
Slide 17: Fast emerging player in international generics
Fast emerging player in international generics All Facilities approved for supply to regulated markets such as the US, Europe, Australia and Brazil Partnership with leading Launching its own front- generic players in the end marketing in the US US, Europe, Canada, Australia Key Highlights 36 ANDAs/N
Slide 18: API business accounts for ~20% of revenues
API business accounts for ~20% of revenues
Slide 19: Focus on Regulated Markets
Focus on Regulated Markets 30% of capacity being used for captive consumption More than 85% Capacity Key of sales are to expansion is in regulated progress Highlights markets / customers 70 DMFs filed
Slide 20: Financial Snapshot
Aes Financial Snapshot
Slide 21: Focus on shareholder value creation
Focus on shareholder value creation 3 Years CAGR 53,738 60,000 Revenue 13% 50,000 EBITDA 28% In INR mn 40,000 19,793 PAT 35% 30,000 9,095 Market Capitalization 143% 20,000 10,000 18,684 - 20,000 Market Capitalization 15,260 FY12 FY13 FY14 14,679 15,000 In INR mn 10,000 3,577 5,000 2,194 2,520 2,355
Slide 22: Financial Highlights
Financial Highlights YTD Dec YTD Dec Particulars (INR mn) Q3FY15 Q3FY14 %Growth FY15 FY14 %Growth Formulations Revenue India Branded 2500 2251 11% 7488 6511 15% Generics 332 289 15% 906 921 -2% International Branded 134 227 -41% 545 560 -3% Generics 1333 1296 3% 3706 3288 13% API Revenue 813 756 7%
Slide 23: Latest Shareholding Pattern
Latest Shareholding Pattern % of Total Shareholding 15 Promoter & Promoter group 11 FI/FII/MF 74 Public Market capitalization INR 84 bn Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn No. of shareholders > 50 K Free float market capitalization INR 22 bn
Slide 24: Way forward
Aes Way forward
Slide 25: Strategy going forward
Strategy going forward • Continue to focus on complex products. Expect to launch 7-9 products every year for the next three years in the US markets • Create a front-end marketing presence in USA in addition to its existing marketing alliances • Filing ANDAs/MAs in other international markets such as
Slide 26: Conference call details
Conference call details Date : Monday, February 4, 2015 Time : 05.00 pm IST India - Primary Number +91 22 39381028 India - Secondary Number +91 22 67468328 USA 1 866 746 2133 UK 0 808 101 1573 Singapore Toll Free No. 800 101 2045 Hong Kong Toll Free No. 800 964 448
Slide 27: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharm
Alembic Pharmaceuticals — Q3 FY2015 Earnings Presentation on 6ix